Athero Review - Issue 3/2025

Abstract Book

Supplementum online: 29th congress on atherosclerosis, 4th – 6th december 2025, Olomouc

Editorial

147

Guidelines

151

Cardio-renal-metabolic syndrome: statement by the Czech Society for Atherosclerosis Committee – year 2025

Hana Rosolová, Jan Piťha, Tomáš Freiberger, Pavel Kraml, Vladimír Blaha, Renata Cífková, David Karásek, Vladimír Soška, Tomáš Štulc, Michal Vrablík, Lukáš Zlatohlávek

Reviews

161

The event is not a coincidence, or the need for long-term and effective cardiovascular risk control

Martin Šatný, Michal Vrablík

167

“RNA Therapy 101”: The basics of RNA therapy in questions and answers

Jan Novák

174

Bempedoic acid – recommended by guidelines, confirmed in practice

Martin Šatný

178

Interactions (not only between genes and the environment) and cardiovascular disease

Jaroslav A. Hubáček

183

Evinacumab – one year of experience in patients with homozygous familial hypercholesterolemia: case reports

Lukáš Zlatohlávek, Jana Beňová Becherová, Jaroslav A. Hubáček

189

Comprehensive lipid-lowering therapy and cardiovascular risk reduction: a case report

Martina Šišáková, Kateřina Helánová

193

Artificial intelligence a double-edged sword for authors – the pitfalls of its use

Jaroslav A. Hubáček

196

Update to ESC/EAS recommendations for dyslipidemia: what‘s new?

Kristýna Čillíková

From International Literature

199

Research on remarkable articles from international literature

Eva Tůmová

Athero Review

2025 Issue 3